Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about enGene Holdings Inc.
enGene Holdings Inc. News
enGene Holdings Inc. Quantitative Score
About enGene Holdings Inc.
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
enGene Holdings Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
enGene Holdings Inc. Financials
Table Compare
Compare ENGN metrics with: | |||
|---|---|---|---|
Earnings & Growth | ENGN | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | ENGN | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | ENGN | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | ENGN | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
enGene Holdings Inc. Income
enGene Holdings Inc. Balance Sheet
enGene Holdings Inc. Cash Flow
enGene Holdings Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Buy |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Neutral |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Buy |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
enGene Holdings Inc. Dividends
| Yield (TTM) | Dividend (TTM) | |
|---|---|---|
Infinity% | 0.5700 |
| Payment Date | Dividend | Frequency |
|---|---|---|
| TBA | 0.13 | Quarterly |
| 2014-12-05 | 0.14 | Quarterly |
| 2014-11-07 | 0.15 | Quarterly |
| 2014-10-07 | 0.15 | Quarterly |
| TBA | 0.13 | Quarterly |
Historical Market Cap
Shares Outstanding
enGene Holdings Inc. Executives
| Name | Role |
|---|---|
| Mr. Ronald H. W. Cooper | President, Chief Executive Officer & Director |
| Dr. Raj S. Pruthi F.A.C.S., M.D., M.H.A. | Chief Medical Officer |
| Dr. Alexander Nichols Ph.D. | Chief Strategy & Operations Officer |
| Dr. Anthony T. Cheung Ph.D. | Co-Founder & Chief Scientific Officer |
| Mr. John C. Brown D.Sc., FRSC, Ph.D. | Co-Founder and Member of Scientific Advisory Board |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. Ronald H. W. Cooper | President, Chief Executive Officer & Director | Male | 1963 | 963.27K |
| Dr. Raj S. Pruthi F.A.C.S., M.D., M.H.A. | Chief Medical Officer | 1967 | 658.59K | |
| Dr. Alexander Nichols Ph.D. | Chief Strategy & Operations Officer | 1986 | 504.44K | |
| Dr. Anthony T. Cheung Ph.D. | Co-Founder & Chief Scientific Officer | 1972 | 341.75K | |
| Mr. John C. Brown D.Sc., FRSC, Ph.D. | Co-Founder and Member of Scientific Advisory Board | Male | -- |
enGene Holdings Inc. Insider Trades
| Date | 8 Jul |
| Name | Boyd Matthew Ross |
| Role | Chief Regulatory Officer |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 100000 |
| Date | 8 Jul |
| Name | Boyd Matthew Ross |
| Role | Chief Regulatory Officer |
| Transaction | Disposed |
| Type | |
| Shares | 0 |
| Date | 8 Jul |
| Name | Boyd Matthew Ross |
| Role | Chief Regulatory Officer |
| Transaction | Disposed |
| Type | |
| Shares | 68000 |
| Date | 8 Jul |
| Name | Boyd Matthew Ross |
| Role | Chief Regulatory Officer |
| Transaction | Disposed |
| Type | |
| Shares | 51000 |
| Date | 8 Jul |
| Name | Astley-Sparke Philip |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 45000 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 8 Jul | Boyd Matthew Ross | Chief Regulatory Officer | Acquired | A-Award | 100000 |
| 8 Jul | Boyd Matthew Ross | Chief Regulatory Officer | Disposed | 0 | |
| 8 Jul | Boyd Matthew Ross | Chief Regulatory Officer | Disposed | 68000 | |
| 8 Jul | Boyd Matthew Ross | Chief Regulatory Officer | Disposed | 51000 | |
| 8 Jul | Astley-Sparke Philip | Director | Acquired | A-Award | 45000 |